Efficacy of Sambucol in the Treatment of Influenza

• Status: Completed
• Trial end date: 2009-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

The trial will examine the efficacy of sambucol in the treatment of influenza. The primary efficacy endpoint will be the length of time to resolution of influenza illness.The double blind trial will be conducted at the Personnel Clinic, and at the Clinical virology Unit, Hadassah University Hospital, and will include 100 patients with laboratory-confirmed influenza infection, 50 in the sambucol and 50 in the placebo study arm.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hadassah Medical Organization
• Collaborator: Razei Bar industries Ltd.

Criteria

Inclusion Criteria:

• Fever ≥ 380C.

• The presence of at least one of the following respiratory symptoms: cough, sore throat, nasal congestion/ runny nose.

• The presence of at least one of the following systemic symptoms: headache, fatigue, myalgia, chills/sweats, malaise.

Exclusion Criteria:

• Pregnant women or women who cannot exclude pregnancy.

• Patients with diabetes.

• Immune-suppressed patients, including patients taking immunosuppressive drugs.

• Patients with renal failure.

• Patients who received the recent influenza vaccine.